DUBLIN–(BUSINESS WIRE)–
Research and Markets has announced the addition of the “Edge Intelligence in the Age of Internet of Things” report to their offering.
This edition of FT TOE covers technological developments and commercial implications of various neuromodulation therapies that are redefining the standard of care offered by traditional drug-based therapies. The issue covers a snapshot of the global neuromodulation industry, highlighting the intensity of research and commercial prospects for newer clinical applications of these therapies. Detailed analysis of the market and technological drivers and challenges are covered, along with their influence on value of care offered to patients. The issue covers four innovation portfolios within this technology sector, including information and analyst insights on potential business models that could redefine healthcare.
The Future Tech TechVision Opportunity Engine (TOE) captures emerging innovations in research and development, or profile existing technologies which have seen a resurgence in terms of new markets and applications. It usually provides a technology overview, drivers, challenges, research and development, analyst insights and key patent information. In some cases, technology convergence scenarios and future growth opportunities are outlined. It covers innovations and technologies in a variety of industry spaces including manufacturing, sensors, electronics, information and communications technologies, networks, lighting technologies, healthcare, medical devices, materials and coatings, and developments in the energy sector that contribute toward a sustainable and greener world.
The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Key Topics Covered:
1. Industry Snapshot of Neuromodulation Therapies
– Most Prescribed Neuromodulation Therapies Target Low Back Pain
– The Clinical Utilization of Neuromodulators is Extending the Way Patients Undertake Therapies
– OEM Efforts to Expand Marketing Channels Are Focused on Widening Clinical Applications
– Demand for Precise Innervation Triggers Initiatives for Improved Design of Stimulation Leads
– Entry of New Participants with Innovative Technologies Affects Pipeline of OEMs
2. Key Technology Developments in Neuromodulation Therapies
– Coin-sized Bioelectronic Device for Chronic Conditions
– Implantable Neuromodulation Therapy for Inflammatory Diseases
– Implantable Neuromodulator for Heart Failure and Hypertension
– Cardiac Contractility Modulation for Chronic Heart Failure
3. IP Landscape of Neuromodulation Therapies
– The United States has Top Rated Jurisdiction for Patents on Neuromodulation Therapies
– Optogenetic Therapies for Movement Disorders
– Implantable Medical Device having a Conducive Coating
4. Analyst Insights
– Demand for Non-invasive and Collaborative Care Drive Technology-enabled Business Models
– OEMs Need to Transfer Cost Savings across the Value Chain when Evaluating Global Growth Strategies
5. Key Contacts
For more information about this report visit http://www.researchandmarkets.com/research/snpsd7/edge_intelligence
View source version on businesswire.com: http://www.businesswire.com/news/home/20170331005285/en/
